Wellington Partners

Wellington Partners is a Munich-based venture capital firm with offices in London and Zurich that invests in technology and life sciences companies across Europe. It targets early-stage and growth-stage opportunities in Digital Media, Software, Electronics and Photonics, Resource Efficiency and Biotech/Life Sciences, including digital health, industrial biotechnology and IT/TMT sectors. The firm provides entrepreneurs with resources to execute their strategies and typically leads rounds, with investments ranging from approximately €0.5 million to €20 million and potential commitments up to €15 million depending on maturity. Since its founding in 1998, it has backed European startups through multiple investment vehicles focused on technology and life sciences.

Frank Boehnke

General Partner

Frank Böhnke

General Partner

Rolf Dienst

General Partner

Johannes Fischer

principal

Ulrich Granzer

Venture Partner

Varun Gupta Ph.D

Principal

Dr. Regina Hodits

Managing Partner

Harald Keller

CFO and Managing Partner

Karl Naegler

Managing Partner

Karl Nagler

Managing Partner

Eberhard Plattfaut Ph.D

Venture Partner

Christian Reitberger Ph.D

General Partner

Dr. Rainer Strohmenger

Managing Partner

Kai Wohlberedt

Associate

Past deals in Switzerland

Polares Medical

Series B in 2020
Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Polares Medical

Series A in 2018
Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Dacuda

Venture Round in 2014
Dacuda is a computer vision company based in Zurich, Switzerland, with additional locations in Palo Alto, California, and Shanghai, China. It specializes in real-time 2D and 3D algorithms that enhance camera capabilities, positioning itself as a pioneer in software 3D camera technology. Dacuda aims to simplify 3D content creation, making it accessible to consumers through app-based scanning solutions. Its technology enables a range of applications, including enhanced user experiences for Augmented and Virtual Reality headsets. Additionally, Dacuda’s innovations include low-cost, real-time image processing that facilitates high-quality scans, effective text recognition, and the conversion of printed text or tables into editable digital formats, thereby streamlining data entry and content sharing. The company has received several prestigious awards for its contributions to technology and innovation.

SENSIMED

Series C in 2012
Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

EWise

Venture Round in 2011
eWise is an international provider of personal financial management and account aggregation solutions, founded in 2000 and headquartered in Switzerland. The company specializes in developing financial service software that enables users to consolidate various financial accounts into a single interface while ensuring robust online security. eWise's Money Manager is utilized by innovative banks worldwide, including major institutions in Europe, Asia, America, and Australia. Their offerings include tools for online payment, account aggregation, security, authentication, and wealth management, catering to the needs of both consumers and financial institutions.

Evolva

Post in 2009
Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Evolva

Series B in 2009
Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Symetis

Series B in 2009
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

SENSIMED

Series A in 2007
Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

Innovative Silicon

Series C in 2007
Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

WLAN AG

Venture Round in 2002
WLAN AG is a wireless local area network distributor. It focuses on the professional client support with regard to evaluation, planning, implementation, operation, and support of WLAN and network access control solutions. It offers its users with network engineering, operations, troubleshooting, and WLAN engineering services. The company offers solutions for network access controlling, public transport systems, and public WLAN. WLAN AG is a Switzerland-based company that was founded in 2004. The company was acquired by Swisscom Eurospot on March 7, 2003.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.